This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA. (ACCCESS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05592002
Recruitment Status : Recruiting
First Posted : October 24, 2022
Last Update Posted : February 13, 2024
Sponsor:
Collaborator:
Nyxoah Inc.
Information provided by (Responsible Party):
Nyxoah S.A.

Brief Summary:
The solution offered by the Genio System to treat OSA patients with CCC using bilateral HGNS has a favorable risk-benefit ratio, as demonstrated by evidence from 2 studies.

Condition or disease Intervention/treatment Phase
Sleep Apnea, Obstructive Device: Genio System Not Applicable

Detailed Description:

Nyxoah has developed the Genio® 2.1 System with the intention of treating patients with moderate to severe obstructive sleep apnea.

In overview, the System includes an Implantable Stimulator (IS) designed to stimulate the hypoglossal nerve branches (i.e., both the left and the right). The IS does not include a battery but receives energy pulses transmitted by an Activation Chip (AC) which is attached to an adhesive Disposable Patch (DP) and placed on the patient's skin under the chin. Stimulation of the hypoglossal nerve causes the tongue muscles to contract with the intention to maintain an open airway.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 124 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter Study to Assess the Safety and Effectiveness of the Genio® Dual-sided Hypoglossal Nerve Stimulation System for the Treatment of Obstructive Sleep Apnea in Subjects With Complete Concentric Collapse of the Soft Palate.
Actual Study Start Date : December 28, 2022
Estimated Primary Completion Date : January 2026
Estimated Study Completion Date : October 2027

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sleep Apnea

Arm Intervention/treatment
Experimental: Genio® 2.1 System
System Component Genio® System 2.1 Implantable Stimulator (IS) Genio® Implantable Stimulator External Stimulator (ES) Genio® External Stimulator Disposable Patch (DP) Genio® Disposable Patch Activation Chip (AC) Genio® Activation Chip (AC) Model #2364 Charging Unit (CU) Genio® Charging Unit (CU) Model #2238 Sleep Lab Application Genio® Sleep Lab Application Smartphone Application (optional) Genio® Smartphone Application
Device: Genio System
The Genio® IS electrode placement does not require an extensive surgical manipulation of the hypoglossal nerve, it requires only a single incision site and does not require battery replacements as those are external components. Whereas UPPP surgery and other similar upper airway enlargement surgeries are much more extensive, are irreversible and tend to have more complications and modest long-term results in reducing OSA severity and symptoms. In summary, the solution offered by the Genio System to treat OSA patients with CCC using bilateral HGNS has a favorable risk-benefit ratio, as demonstrated by evidence from 2 studies.
Other Name: Genio System 2.0




Primary Outcome Measures :
  1. Primary Effectiveness Endpoint [ Time Frame: The duration of the study is expected to be approximately 4.5 years. ]
    The effectiveness endpoint of the study is assessed through the reduction in the severity of OSA over a period of 12 months post-implant. Primary effectiveness endpoint: percentage of responders based on a change in apnea-hypopnea index (AHI4) and oxygen desaturation index (ODI4) at 12 months post-activation. A responder is defined as any subject with a reduction of 50% in AHI4 from Baseline and a remaining AHI4 < 20 events/hour (aka "Sher Criteria"), AND 25% in ODI4 from Baseline.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1. Age from 22 to 75 years (inclusive). Participant cannot be under guardianship, under curatorship or under judicial protection.

    2. Body mass index (BMI) ≤ 32 kg/m2. 3. Positive cricomental space (≥ 0 cm). The cricomental space is the distance between the neck and the bisection of a line from the chin to the cricoid membrane when the head is in a neutral position.

    4. Has either not tolerated, has failed or refused positive airway pressure (PAP) treatments.

    5. Moderate to severe OSA (15≤AHI4≤65 where combined central and mixed AHI<25% of the total AHI) based on a screening HST and confirmed in Baseline PSG.

    6. Complete concentric collapse at the level of the soft palate based on screening DISE.

    7. Willing and capable of complying with all study requirements, including specific lifestyle considerations, performing all follow-up visits and sleep studies, evaluation procedures and questionnaires for the whole duration of the trial.

  • Exclusion Criteria:

    1. Inadequately treated sleep disorders other than OSA that would confound functional sleep assessment:

      1. Severe chronic insomnia,
      2. Insufficient sleep syndrome (<6 hours sleep per night),
      3. Narcolepsy,
      4. Restless legs syndrome,
      5. REM behavior disorder,
      6. Others deemed sufficient disorders that would confound functional sleep assessment in the judgment of the investigator.
    2. Taking medications that may alter consciousness, the pattern of respiration, or sleep architecture as determined by the investigator.
    3. Major anatomical or functional abnormalities that would impair the ability of the Genio® System to treat OSA:

      1. Craniofacial abnormalities narrowing the airway or the implantation site,
      2. Palatine tonsil size 3+ or 4+ by the Brodsky Classification,
      3. Fixed upper airway obstructions (tumor, polyps, nasal obstruction),
      4. Congenital malformations in the airway,
      5. Hypoglossal nerve palsy (bilateral limited tongue movement, or unilateral unintended tongue deviation during protrusion),
      6. Existing swallowing difficulty as measured by a score of ≥3 on the EAT-10 questionnaire
      7. Others deemed sufficient to impair the ability of the Genio® System to treat OSA in the judgment of the investigator.
    4. Significant comorbidities that contraindicate surgery or general anesthesia:

      1. Revised Cardiac Risk Index Class III or IV,
      2. Persistent uncontrolled diagnosed hypertension despite medications,
      3. Coagulopathy or required anticoagulant medications (such as warfarin, clopidogrel (Plavix) or similar; prophylactic aspirin not exclusionary) that cannot be safely stopped in the perioperative period, Subjects meeting any of the following criteria will be excluded from participation in this study:
    1. Inadequately treated sleep disorders other than OSA that would confound functional sleep assessment:

      1. Severe chronic insomnia,
      2. Insufficient sleep syndrome (<6 hours sleep per night),
      3. Narcolepsy,
      4. Restless legs syndrome,
      5. REM behavior disorder,
      6. Others deemed sufficient disorders that would confound functional sleep assessment in the judgment of the investigator.
    2. Taking medications that may alter consciousness, the pattern of respiration, or sleep architecture as determined by the investigator.
    3. Major anatomical or functional abnormalities that would impair the ability of the Genio® System to treat OSA:

      1. Craniofacial abnormalities narrowing the airway or the implantation site,
      2. Palatine tonsil size 3+ or 4+ by the Brodsky Classification,
      3. Fixed upper airway obstructions (tumor, polyps, nasal obstruction),
      4. Congenital malformations in the airway,
      5. Hypoglossal nerve palsy (bilateral limited tongue movement, or unilateral unintended tongue deviation during protrusion),
      6. Existing swallowing difficulty as measured by a score of ≥3 on the EAT-10 questionnaire
      7. Others deemed sufficient to impair the ability of the Genio® System to treat OSA in the judgment of the investigator.
    4. Significant comorbidities that contraindicate surgery or general anesthesia:

      1. Revised Cardiac Risk Index Class III or IV,
      2. Persistent uncontrolled diagnosed hypertension despite medications,
      3. Coagulopathy or required anticoagulant medications (such as warfarin, clopidogrel (Plavix) or similar; prophylactic aspirin not exclusionary) that cannot be safely stopped in the perioperative period,
      4. Degenerative neurological disorder (i.e., Parkinson's disease, Alzheimer's disease),
      5. Acute illness or infection,
      6. Any other chronic medical illness or condition that contraindicates a surgical procedure or general anesthesia in the judgment of the investigator.
    5. Diagnosed psychiatric disease (e.g., psychotic illness, uncontrolled major depression or acute anxiety attacks) that prevents participant compliance with the requirements of the investigational study testing,
    6. Substance or alcohol abuse history within the previous 3 years. Alcohol and substance abuse are defined as follows:

      i. Alcohol: no days with less than 3 or 4 standard drinks for women and men respectively ii. Substance: the use of any substance in an amount unapproved by the investigator or considered illegal. The drugs most commonly abused include cocaine, marijuana, heroin (or substitution treatment), prescription drugs (especially painkillers), methamphetamines, and various other illegal substances.

    7. Life expectancy of less than 12 months.
    8. Prior surgery or treatments that could compromise the effectiveness of the Genio® System:

      1. Airway cancer surgery or radiation,
      2. Mandible or maxilla surgery in the previous 5 years (not counting dental treatments),
      3. Other upper airway surgery to remove obstructions related to OSA in the previous 3 months (e.g., uvulopalatopharyngoplasty (UPPP), tonsillectomy, nasal airway surgery),
      4. Prior hypoglossal nerve stimulation device implantation.
    9. Has an Active Implantable Medical Device (AIMD) even if the device can be temporarily turned off.
    10. Participation in another clinical study with an active treatment arm.
    11. Plan to become pregnant, currently pregnant, or breastfeeding during the study period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05592002


Contacts
Layout table for location contacts
Contact: Joyce Babayan 818-388-1001 Joyce.Babayan@nyxoah.com
Contact: Jey Subarroyan, PhD 734-277-3273 Jey.Subarroyan@nyxoah.com

Locations
Layout table for location information
United States, Colorado
Colorado ENT & Allergy Recruiting
Colorado Springs, Colorado, United States, 80923
Contact: Monica Davis         
United States, Florida
ENT and Allergy Associates of Florida, LLC Recruiting
Boca Raton, Florida, United States, 33487
Contact: Sandy DiBattista         
Principal Investigator: Melyssa Hancock, MD         
University of Miami Recruiting
Miami, Florida, United States, 33136
Contact: Komal Parikh         
PharmaDev Clinical Research Institute, Recruiting
Miami, Florida, United States, 33176
Contact: Olivia Falcon Valdes         
United States, Indiana
Center for ENT and Allergy, PC Ascension Medical Group Recruiting
Carmel, Indiana, United States, 46032
Contact: Grace Newhart         
United States, Iowa
University of Iowa Institute for Clinical & Translational Science Recruiting
Iowa City, Iowa, United States, 52242
Contact: Judith Leon         
United States, Kansas
University of Kansas Recruiting
Kansas City, Kansas, United States, 66160
Contact: Bryan Humphrey         
United States, Massachusetts
Massachusetts Eye & Ear Recruiting
Boston, Massachusetts, United States, 02114
Contact: Brendan McBrine         
United States, Pennsylvania
Thomas Jefferson University Department of Otolaryngology Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Susan Walker, RN         
United States, Tennessee
Vanderbilt University Medical Center Recruiting
Nashville, Tennessee, United States, 37232
Contact: Kate VonWahlde         
United States, Virginia
Eastern Virginia Medical School Recruiting
Norfolk, Virginia, United States, 23507
Contact: Patrick Felan         
Sponsors and Collaborators
Nyxoah S.A.
Nyxoah Inc.
Investigators
Layout table for investigator information
Study Director: Jey Subarroyan, PhD Nyxoah S.A.
Layout table for additonal information
Responsible Party: Nyxoah S.A.
ClinicalTrials.gov Identifier: NCT05592002    
Other Study ID Numbers: CL-CCC2022
First Posted: October 24, 2022    Key Record Dates
Last Update Posted: February 13, 2024
Last Verified: February 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Apnea
Respiration Disorders
Respiratory Tract Diseases
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases